The U.S. Food and Drug Administration has approved Sanofi-Aventis's Merilog (insulin-aspart-szjj ... Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included ...

The approval is for both a 3 milliliter (mL) single-patient-use prefilled pen and a 10 milliliter ... The FDA granted approval of Merilog to Sanofi-Aventis U.S. LLC. “The FDA has now approved three ...

This disposable insulin pen is to be used for the treatment of ... the name of the parent company was changed globally from sanofi-aventis to Sanofi in May 2011.On 9 October 2012, Sanofi India ...

On February 14, 2025, the U.S. Food and Drug Administration (“FDA”) approved Sanofi-Aventis ... pen and a 10 mL multiple-dose vial. Sanofi’s MERILOG™ is now the first insulin aspart ...

The US Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.

(RTTNews) - The U.S. Food and Drug Administration announced that Sanofi-Aventis U.S ... use prefilled pen and a 10 mL multiple-dose vial. As a rapid-acting human insulin, Merilog helps to lower ...

Sanofi-Aventis' Merilog version ... options for costly treatments, like insulin." Merilog has been cleared in a 3ml single-patient-use prefilled pen, and a 10ml multiple-dose vial should be ...

vial or cartridge Lantus vial or cartridge (Sanofi-Aventis) 28 days Prescribing information 70% insulin aspart protamine suspension and 30% insulin as part injection (rDNA origin) pen fill ...

WEDNESDAY, Feb. 19, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj ... of Merilog was granted to Sanofi-Aventis.